JP2012508223A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012508223A5 JP2012508223A5 JP2011535182A JP2011535182A JP2012508223A5 JP 2012508223 A5 JP2012508223 A5 JP 2012508223A5 JP 2011535182 A JP2011535182 A JP 2011535182A JP 2011535182 A JP2011535182 A JP 2011535182A JP 2012508223 A5 JP2012508223 A5 JP 2012508223A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- triazin
- alkyl
- pyridin
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 25
- 125000000623 heterocyclic group Chemical group 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000003118 aryl group Chemical group 0.000 claims 19
- 125000001072 heteroaryl group Chemical group 0.000 claims 19
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 16
- 125000004452 carbocyclyl group Chemical group 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 10
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 229910052794 bromium Inorganic materials 0.000 claims 9
- 229910052801 chlorine Inorganic materials 0.000 claims 9
- 229910052731 fluorine Inorganic materials 0.000 claims 9
- 229910052740 iodine Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000005647 linker group Chemical group 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 230000003796 beauty Effects 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 230000003463 hyperproliferative effect Effects 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 125000003860 C1-C20 alkoxy group Chemical group 0.000 claims 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 2
- 208000006029 Cardiomegaly Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 230000006044 T cell activation Effects 0.000 claims 2
- 108090000190 Thrombin Proteins 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 230000001066 destructive effect Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 208000033065 inborn errors of immunity Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- 150000003456 sulfonamides Chemical class 0.000 claims 2
- 229960004072 thrombin Drugs 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical group C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 1
- WMHAVCWMHYZXHG-UHFFFAOYSA-N 3-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenol Chemical compound OC1=CC=CC(C=2N=C(N=C(N=2)N2CCOCC2)N2CCOCC2)=C1 WMHAVCWMHYZXHG-UHFFFAOYSA-N 0.000 claims 1
- CONLCFVHCYLZKW-UHFFFAOYSA-N 3-[4-morpholin-4-yl-6-(pyridin-2-ylmethylamino)-1,3,5-triazin-2-yl]phenol Chemical compound OC1=CC=CC(C=2N=C(N=C(NCC=3N=CC=CC=3)N=2)N2CCOCC2)=C1 CONLCFVHCYLZKW-UHFFFAOYSA-N 0.000 claims 1
- KAMYTFFDGJCUCA-UHFFFAOYSA-N 4-(1h-benzimidazol-4-yl)-6-morpholin-4-yl-n-(pyridin-2-ylmethyl)-1,3,5-triazin-2-amine Chemical compound C=1C=CC=NC=1CNC(N=C(N=1)C=2C=3N=CNC=3C=CC=2)=NC=1N1CCOCC1 KAMYTFFDGJCUCA-UHFFFAOYSA-N 0.000 claims 1
- NNOOIRJOIGXMEE-UHFFFAOYSA-N 4-(1h-indazol-5-yl)-6-morpholin-4-yl-n-(pyridin-2-ylmethyl)-1,3,5-triazin-2-amine Chemical compound C=1C=CC=NC=1CNC(N=C(N=1)C=2C=C3C=NNC3=CC=2)=NC=1N1CCOCC1 NNOOIRJOIGXMEE-UHFFFAOYSA-N 0.000 claims 1
- AZIIYUJTCFFXTJ-UHFFFAOYSA-N 4-(1h-indol-4-yl)-6-morpholin-4-yl-n-(pyridin-2-ylmethyl)-1,3,5-triazin-2-amine Chemical compound C=1C=CC=NC=1CNC(N=C(N=1)C=2C=3C=CNC=3C=CC=2)=NC=1N1CCOCC1 AZIIYUJTCFFXTJ-UHFFFAOYSA-N 0.000 claims 1
- WRVPFLBQQXTMEU-UHFFFAOYSA-N 4-(1h-indol-5-yl)-6-morpholin-4-yl-n-(pyridin-2-ylmethyl)-1,3,5-triazin-2-amine Chemical compound C=1C=CC=NC=1CNC(N=C(N=1)C=2C=C3C=CNC3=CC=2)=NC=1N1CCOCC1 WRVPFLBQQXTMEU-UHFFFAOYSA-N 0.000 claims 1
- MDHMXHNFPXWJEG-UHFFFAOYSA-N 4-(2-aminopyrimidin-5-yl)-6-morpholin-4-yl-n-(pyridin-2-ylmethyl)-1,3,5-triazin-2-amine Chemical compound C1=NC(N)=NC=C1C1=NC(NCC=2N=CC=CC=2)=NC(N2CCOCC2)=N1 MDHMXHNFPXWJEG-UHFFFAOYSA-N 0.000 claims 1
- VMXPZMLXTHXGLQ-UHFFFAOYSA-N 4-(3h-benzimidazol-5-yl)-6-morpholin-4-yl-n-(pyridin-2-ylmethyl)-1,3,5-triazin-2-amine Chemical compound C=1C=CC=NC=1CNC(N=C(N=1)C=2C=C3N=CNC3=CC=2)=NC=1N1CCOCC1 VMXPZMLXTHXGLQ-UHFFFAOYSA-N 0.000 claims 1
- CAVNILDGKKVJSJ-UHFFFAOYSA-N 4-(6-aminopyridin-3-yl)-6-morpholin-4-yl-n-(pyridin-2-ylmethyl)-1,3,5-triazin-2-amine Chemical compound C1=NC(N)=CC=C1C1=NC(NCC=2N=CC=CC=2)=NC(N2CCOCC2)=N1 CAVNILDGKKVJSJ-UHFFFAOYSA-N 0.000 claims 1
- BBDMJQBDNFISIX-UHFFFAOYSA-N 4-[4-(1h-benzimidazol-4-yl)-6-(pyridin-2-ylmethoxy)-1,3,5-triazin-2-yl]morpholine Chemical compound C=1C=CC=NC=1COC(N=C(N=1)C=2C=3N=CNC=3C=CC=2)=NC=1N1CCOCC1 BBDMJQBDNFISIX-UHFFFAOYSA-N 0.000 claims 1
- UPZKDZOZSLCPDX-UHFFFAOYSA-N 4-[4-(1h-indazol-4-yl)-6-(pyridin-2-ylmethoxy)-1,3,5-triazin-2-yl]morpholine Chemical compound C=1C=CC=NC=1COC(N=C(N=1)C=2C=3C=NNC=3C=CC=2)=NC=1N1CCOCC1 UPZKDZOZSLCPDX-UHFFFAOYSA-N 0.000 claims 1
- AYCPQGCCBNIKNU-UHFFFAOYSA-N 4-[4-(1h-indazol-5-yl)-6-(pyridin-2-ylmethoxy)-1,3,5-triazin-2-yl]morpholine Chemical compound C=1C=CC=NC=1COC(N=C(N=1)C=2C=C3C=NNC3=CC=2)=NC=1N1CCOCC1 AYCPQGCCBNIKNU-UHFFFAOYSA-N 0.000 claims 1
- BWHGEHLHWRIFSI-UHFFFAOYSA-N 4-[4-(1h-indol-4-yl)-6-(pyridin-2-ylmethoxy)-1,3,5-triazin-2-yl]morpholine Chemical compound C=1C=CC=NC=1COC(N=C(N=1)C=2C=3C=CNC=3C=CC=2)=NC=1N1CCOCC1 BWHGEHLHWRIFSI-UHFFFAOYSA-N 0.000 claims 1
- DDQOBEBNFDEMIW-UHFFFAOYSA-N 4-[4-(1h-indol-5-yl)-6-(pyridin-2-ylmethoxy)-1,3,5-triazin-2-yl]morpholine Chemical compound C=1C=CC=NC=1COC(N=C(N=1)C=2C=C3C=CNC3=CC=2)=NC=1N1CCOCC1 DDQOBEBNFDEMIW-UHFFFAOYSA-N 0.000 claims 1
- ADGGYDAFIHSYFI-UHFFFAOYSA-N 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1 ADGGYDAFIHSYFI-UHFFFAOYSA-N 0.000 claims 1
- IFPHRQQBRZZIOQ-UHFFFAOYSA-N 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyrimidin-2-amine Chemical compound FC(F)(F)C1=NC(N)=NC=C1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1 IFPHRQQBRZZIOQ-UHFFFAOYSA-N 0.000 claims 1
- OCKCSFKWKYZXKV-UHFFFAOYSA-N 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-6-(trifluoromethyl)pyridin-2-amine Chemical compound FC(F)(F)C1=NC(N)=CC=C1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1 OCKCSFKWKYZXKV-UHFFFAOYSA-N 0.000 claims 1
- WIVHSFPCDNBXSB-UHFFFAOYSA-N 5-[4-morpholin-4-yl-6-(pyridin-2-ylmethoxy)-1,3,5-triazin-2-yl]pyridin-2-amine Chemical compound C1=NC(N)=CC=C1C1=NC(OCC=2N=CC=CC=2)=NC(N2CCOCC2)=N1 WIVHSFPCDNBXSB-UHFFFAOYSA-N 0.000 claims 1
- HGNGQAXXKVMOMI-UHFFFAOYSA-N 5-[4-morpholin-4-yl-6-(pyridin-2-ylmethoxy)-1,3,5-triazin-2-yl]pyrimidin-2-amine Chemical compound C1=NC(N)=NC=C1C1=NC(OCC=2N=CC=CC=2)=NC(N2CCOCC2)=N1 HGNGQAXXKVMOMI-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- VEFTXXDQMDONGC-UHFFFAOYSA-N C1COCCN1C2N=CN=C(N2C3=CC4=C(C=C3)N=CN4)OCC5=CC=CC=N5 Chemical compound C1COCCN1C2N=CN=C(N2C3=CC4=C(C=C3)N=CN4)OCC5=CC=CC=N5 VEFTXXDQMDONGC-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091007960 PI3Ks Proteins 0.000 claims 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000002952 polymeric resin Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims 1
- 150000003457 sulfones Chemical class 0.000 claims 1
- 229920003002 synthetic resin Polymers 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 0 *C(*1)C(C2N=C(N3C(*)C(*)OC(*)C3*)N=C(*)C2)=C(*)N=C1N* Chemical compound *C(*1)C(C2N=C(N3C(*)C(*)OC(*)C3*)N=C(*)C2)=C(*)N=C1N* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0821219A GB2465405A (en) | 2008-11-10 | 2008-11-10 | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| GB08211219.3 | 2008-11-10 | ||
| PCT/IB2009/007404 WO2010052569A2 (en) | 2008-11-10 | 2009-11-10 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015020319A Division JP6047184B2 (ja) | 2008-11-10 | 2015-02-04 | トリアジン、ピリミジン、及びピリジン類似体、並びに、治療薬及び診断プローブとしてのそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012508223A JP2012508223A (ja) | 2012-04-05 |
| JP2012508223A5 true JP2012508223A5 (enExample) | 2012-12-27 |
| JP5738768B2 JP5738768B2 (ja) | 2015-06-24 |
Family
ID=40230564
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011535182A Active JP5738768B2 (ja) | 2008-11-10 | 2009-11-10 | トリアジン、ピリミジン、及びピリジン類似体、並びに、治療薬及び診断プローブとしてのそれらの使用 |
| JP2015020319A Active JP6047184B2 (ja) | 2008-11-10 | 2015-02-04 | トリアジン、ピリミジン、及びピリジン類似体、並びに、治療薬及び診断プローブとしてのそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015020319A Active JP6047184B2 (ja) | 2008-11-10 | 2015-02-04 | トリアジン、ピリミジン、及びピリジン類似体、並びに、治療薬及び診断プローブとしてのそれらの使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8921361B2 (enExample) |
| EP (1) | EP2364302B1 (enExample) |
| JP (2) | JP5738768B2 (enExample) |
| KR (1) | KR101749192B1 (enExample) |
| CN (1) | CN102209714B (enExample) |
| AU (1) | AU2009312464B2 (enExample) |
| BR (1) | BRPI0921709B1 (enExample) |
| CA (1) | CA2741990C (enExample) |
| CY (1) | CY1118438T1 (enExample) |
| DK (1) | DK2364302T3 (enExample) |
| ES (1) | ES2609296T3 (enExample) |
| GB (1) | GB2465405A (enExample) |
| HR (1) | HRP20161769T1 (enExample) |
| IL (1) | IL212726A (enExample) |
| LT (1) | LT2364302T (enExample) |
| MX (1) | MX2011004889A (enExample) |
| NZ (1) | NZ592617A (enExample) |
| RU (1) | RU2537945C2 (enExample) |
| SI (1) | SI2364302T1 (enExample) |
| SM (1) | SMT201700006B (enExample) |
| WO (1) | WO2010052569A2 (enExample) |
| ZA (1) | ZA201104298B (enExample) |
Families Citing this family (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3086695B2 (ja) | 1990-07-20 | 2000-09-11 | 株式会社東芝 | ガスタービン制御装置 |
| GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| US8461158B2 (en) | 2009-03-27 | 2013-06-11 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
| UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| US8486939B2 (en) | 2009-07-07 | 2013-07-16 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| JP5746172B2 (ja) | 2009-08-20 | 2015-07-08 | カルス セラピューティクス リミテッド | ホスホイノシチド３−キナーゼ阻害剤としての三環式複素環化合物 |
| EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
| EP2542536B1 (en) | 2010-03-04 | 2015-01-21 | Cellzome Limited | Morpholino substituted urea derivatives as mtor inhibitors |
| EP2616441B1 (en) | 2010-09-17 | 2019-08-07 | Purdue Pharma L.P. | Pyridine compounds and the uses thereof |
| AU2015268776B2 (en) * | 2010-12-16 | 2017-04-13 | Genentech, Inc. | Tricyclic PI3k inhibitor compounds and methods of use |
| CA2820078C (en) * | 2010-12-16 | 2019-02-12 | F. Hoffmann-La Roche Ag | Tricyclic pi3k inhibitor compounds and methods of use |
| CA2822789A1 (en) * | 2010-12-22 | 2012-06-28 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
| EP2667874A4 (en) * | 2011-01-27 | 2014-07-30 | Univ Princeton | MTOR KINASE HEMMER AS ANTIVIRUS AGENT |
| EP2683243A4 (en) * | 2011-03-09 | 2014-12-03 | Celgene Avilomics Res Inc | PI3 KINASE INHIBITORS AND USES THEREOF |
| CA2831582C (en) | 2011-03-28 | 2019-01-08 | Mei Pharma, Inc. | (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
| CN102389430B (zh) * | 2011-09-07 | 2013-08-28 | 苏州大学 | 一种小分子化合物在制备抗肺癌药物中的应用 |
| EP2758379B1 (en) * | 2011-09-21 | 2016-10-19 | Cellzome Limited | Urea and carbamate derivatives of 2-morpholino-1,3,5-triazine as mTOR inhibitors for the treatment of immunological or proliferative diseases |
| EP2771337B1 (en) | 2011-09-27 | 2017-08-02 | Novartis AG | 3-(pyrimidin-4-yl)-oxazolidin-2-ones as inhibitors of mutant idh |
| AU2012320465B2 (en) * | 2011-10-07 | 2016-03-03 | Cellzome Limited | Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| EP2828269B1 (en) * | 2012-03-19 | 2018-05-16 | Council of Scientific & Industrial Research | Boronic acid bearing liphagane compounds as inhibitors of pi3k-alpha and/or beta |
| US9630958B2 (en) | 2012-07-23 | 2017-04-25 | Sphaera Pharma Pte. Ltd. | Triazine compounds |
| US10249827B2 (en) | 2012-09-20 | 2019-04-02 | Udc Ireland Limited | Azadibenzofurans for electronic applications |
| CN102875558A (zh) * | 2012-11-05 | 2013-01-16 | 贵州大学 | 2-氯-4-取代-8-硝基苯并呋喃[3,2-d]嘧啶类化合物及其制备方法和用途 |
| AU2013343291B2 (en) | 2012-11-07 | 2018-05-10 | Karus Therapeutics Ltd | Novel histone deacetylase inhibitors and their use in therapy |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| WO2014110466A1 (en) * | 2013-01-12 | 2014-07-17 | Dawei Zhang | Pyridine compounds used as pi3 kinase inhibitors |
| WO2014141104A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| MY182082A (en) * | 2013-05-01 | 2021-01-18 | Hoffmann La Roche | Biheteroaryl compounds and uses thereof |
| EP2994465B1 (en) | 2013-05-10 | 2018-08-15 | Karus Therapeutics Limited | Novel histone deacetylase inhibitors |
| CN103483345B (zh) * | 2013-09-25 | 2016-07-06 | 中山大学 | Pi3k激酶抑制剂、包含其的药物组合物及其应用 |
| WO2015088564A1 (en) * | 2013-12-13 | 2015-06-18 | Sunovion Pharmaceuticals Inc. | P2x4 receptor modulating compounds |
| WO2015088565A1 (en) * | 2013-12-13 | 2015-06-18 | Sunovion Pharmaceuticals Inc. | P2x4 receptor modulating compounds and methods of use thereof |
| GB201402431D0 (en) * | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| KR102256898B1 (ko) | 2014-04-02 | 2021-05-31 | 이네오스 스티롤루션 그룹 게엠베하 | 개선된 기계적 특성을 지닌 열가소성 성형 조성물의 제조 방법 |
| EP3134388B1 (en) * | 2014-04-22 | 2019-01-09 | Universität Basel | Novel manufacturing process for triazine, pyrimidine and pyridine derivatives |
| KR102287012B1 (ko) * | 2014-05-28 | 2021-08-09 | 덕산네오룩스 주식회사 | 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치 |
| LT3177612T (lt) | 2014-08-04 | 2022-06-10 | Nuevolution A/S | Pirimidino dariniai, pakeisti pasirinktinai kondensuotu heterociklilu, tinkami uždegiminių, metabolinių, onkologinių ir autoimuninių ligų gydymui |
| CN104151256B (zh) * | 2014-08-14 | 2016-08-24 | 西安交通大学 | 二取代苯甲酰胺类化合物及其合成方法和应用 |
| GB201419228D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| GB201419264D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| MA40933A (fr) * | 2014-11-11 | 2017-09-19 | Piqur Therapeutics Ag | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines |
| CN104473923B (zh) * | 2014-12-29 | 2016-08-17 | 巩春智 | 一种防治慢性心力衰竭的药物组合物及其应用 |
| TW201636329A (zh) | 2015-02-02 | 2016-10-16 | 佛瑪治療公司 | 作為ｈｄａｃ抑制劑之雙環［４，６，０］異羥肟酸 |
| ES2770123T3 (es) | 2015-02-02 | 2020-06-30 | Forma Therapeutics Inc | Acidos 3-alquil-4-amido-bicíclicos [4,5,0]hidroxámicos como inhibidores de HDAC |
| CN104860956B (zh) * | 2015-04-30 | 2017-05-10 | 华南师范大学 | 一种荧光多功能单体及其合成方法与应用 |
| CN106279211B (zh) * | 2015-06-03 | 2020-09-15 | 北京大学 | 一种噻唑并嘧啶酮化合物及其制备方法和应用 |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| CN110946865B (zh) | 2015-12-10 | 2024-01-26 | Ptc医疗公司 | 用于治疗亨廷顿病的方法 |
| DK3389662T3 (da) * | 2015-12-16 | 2022-02-28 | Genentech Inc | Fremgangsmåde til fremstilling af tricykliske PI3K-inhibitorforbindelser og fremgangsmåder til anvendelse af disse til behandling af cancer |
| GB201602527D0 (en) * | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| KR101919189B1 (ko) * | 2016-02-18 | 2018-11-15 | 경북대학교 산학협력단 | 다중치환 4H-티아졸로[4,5-e][1,4]다이아제핀-5,8-다이온 유도체 및 이의 용도 |
| LT3416957T (lt) | 2016-02-19 | 2020-11-25 | Sprint Bioscience Ab | 6-heterociklil-4-morfolin-4-ilpiridin-2-ono junginiai, tinkami vėžio ir diabeto gydymui |
| AU2017219846B2 (en) | 2016-02-19 | 2021-05-13 | Sprint Bioscience Ab | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| CN109414415B (zh) * | 2016-05-18 | 2023-05-02 | 拓客股份有限公司 | 皮肤病变的治疗 |
| MX2018014168A (es) * | 2016-05-18 | 2019-04-29 | Piqur Therapeutics Ag | Tratamiento de transtornos neurologicos. |
| EP3458035A1 (en) * | 2016-05-18 | 2019-03-27 | PIQUR Therapeutics AG | Treatment of skin lesions |
| AU2017275657B2 (en) | 2016-06-02 | 2021-08-19 | Novartis Ag | Potassium channel modulators |
| EP3472131B1 (en) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
| CA3030021A1 (en) * | 2016-07-07 | 2018-01-11 | Cardurion Pharmaceuticals, Llc | Methods for treatment of heart failure |
| WO2018102552A1 (en) | 2016-11-30 | 2018-06-07 | Case Western Reserve University | Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof |
| EP3558971B1 (en) | 2016-12-22 | 2022-02-23 | Global Blood Therapeutics, Inc. | Histone methyltransferase inhibitors |
| UA123810C2 (uk) | 2017-01-23 | 2021-06-02 | Цадент Терапеутікс, Інк. | Модулятори калієвих каналів |
| US11718589B2 (en) | 2017-02-06 | 2023-08-08 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase |
| GB201702938D0 (en) | 2017-02-23 | 2017-04-12 | Univ Southampton | Methods of generating and screening compartmentalised peptides libraries |
| CA3063976A1 (en) | 2017-05-23 | 2018-11-29 | Mei Pharma, Inc. | Combination therapy |
| CN107216344B (zh) * | 2017-05-27 | 2019-06-21 | 无锡捷化医药科技有限公司 | 一种5-溴-噻唑并[4,5-d]嘧啶的制备方法 |
| EP3634953B1 (en) | 2017-06-05 | 2024-01-03 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| CN110997671A (zh) * | 2017-06-09 | 2020-04-10 | 全球血液疗法股份有限公司 | 作为组蛋白甲基转移酶抑制剂的氮杂吲哚化合物 |
| CN107266422A (zh) * | 2017-06-12 | 2017-10-20 | 西安交通大学 | 2‑（5‑嘧啶基）‑4‑吗啉基‑6‑取代均三嗪类化合物及其盐、制备方法和应用 |
| CN111163838B (zh) | 2017-06-28 | 2023-03-28 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| MX2019015578A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| MX2020001727A (es) | 2017-08-14 | 2020-03-20 | Mei Pharma Inc | Terapia de combinacion. |
| CN109651341A (zh) * | 2017-10-11 | 2019-04-19 | 上海医药工业研究院 | 二吗啉氰基嘧(吡)啶类衍生物及作为抗肿瘤药物应用 |
| BR112020009855A8 (pt) * | 2017-11-23 | 2023-01-10 | Piqur Therapeutics Ag | Tratamento de distúrbios de pele |
| FI3753937T3 (fi) | 2018-02-07 | 2024-01-31 | Wuxi Biocity Biopharmaceutics Co Ltd | Atr-inhibiittori ja sen sovellus |
| JP7399870B2 (ja) | 2018-03-27 | 2023-12-18 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための化合物 |
| ES3032793T3 (en) * | 2018-04-10 | 2025-07-24 | Neuropore Therapies Inc | Tri-substituted aryl and heteroaryl derivatives as modulators of pi3-kinase and autophagy pathways |
| PE20211480A1 (es) | 2018-04-17 | 2021-08-05 | Cardurion Pharmaceuticals Llc | Sales de meglumina de tienopirimidinas |
| PL3814357T3 (pl) | 2018-06-27 | 2024-09-16 | Ptc Therapeutics, Inc. | Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona |
| KR20210038845A (ko) | 2018-06-27 | 2021-04-08 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료를 위한 헤테로아릴 화합물 |
| EP3814360B8 (en) | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| EP3833784A1 (en) | 2018-08-07 | 2021-06-16 | PIQUR Therapeutics AG | Treatment of squamous cell carcinoma |
| MX2021004647A (es) | 2018-10-22 | 2021-08-16 | Novartis Ag | Formas cristalinas de moduladores de los canales de potasio. |
| KR102921276B1 (ko) | 2018-11-21 | 2026-02-03 | 케이스 웨스턴 리저브 유니버시티 | 단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법 |
| TW202039481A (zh) | 2018-12-21 | 2020-11-01 | 美商西建公司 | Ripk2之噻吩并吡啶抑制劑 |
| KR20210112316A (ko) * | 2019-01-04 | 2021-09-14 | 벨부르크 랩스, 엘엘씨 | 치료제로서의 cgas 활성 억제제 |
| MX2021009142A (es) | 2019-02-06 | 2021-10-13 | Venthera Inc | Inhibidores topicos de fosfoinositol 3-cinasas. |
| CN109942562B (zh) * | 2019-02-27 | 2022-02-08 | 江西科技师范大学 | 含芳基结构的五元杂环联三嗪类化合物及其制备方法和应用 |
| CN114245794B (zh) | 2019-05-13 | 2024-09-13 | Ptc医疗公司 | 用于治疗亨廷顿氏病的化合物 |
| GB201909468D0 (en) | 2019-07-01 | 2019-08-14 | Karus Therapeutics Ltd | Compounds for treating cancer |
| EP3994142A4 (en) * | 2019-07-03 | 2023-09-06 | Borah, Inc. | CHEMICAL COMPOUNDS |
| TWI872177B (zh) | 2019-12-20 | 2025-02-11 | 丹麥商紐韋盧森公司 | 對核受體具有活性之化合物 |
| MX2022007265A (es) | 2019-12-20 | 2022-09-09 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
| KR20220140515A (ko) | 2020-01-13 | 2022-10-18 | 버지 애널리틱스, 인크. | 치환된 피라졸로-피리미딘 및 그의 용도 |
| US11780843B2 (en) | 2020-03-31 | 2023-10-10 | Nuevolution A/S | Compounds active towards nuclear receptors |
| US11613532B2 (en) | 2020-03-31 | 2023-03-28 | Nuevolution A/S | Compounds active towards nuclear receptors |
| JP2023550638A (ja) | 2020-11-25 | 2023-12-04 | デシフェラ・ファーマシューティカルズ，エルエルシー | ウイルス感染症の処置に使用するための、ｖｓｐ３４阻害剤としてのモルホリノ誘導体 |
| EP4281447A4 (en) * | 2021-01-25 | 2025-06-04 | Athos Therapeutics, Inc. | TRIAZINE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME |
| EP4320110A1 (en) * | 2021-04-09 | 2024-02-14 | Universität Basel | Triazine derivative as covalent inhibitors of pi3k |
| JP2024516361A (ja) * | 2021-04-09 | 2024-04-15 | ウニヴェアズィテート バーゼル | Ｐｉ３ｋの可逆的および不可逆的共有結合性阻害剤としてのトリアジン誘導体 |
| CN117396470A (zh) * | 2021-04-09 | 2024-01-12 | 巴塞尔大学 | 作为pi3k的可逆和不可逆共价抑制剂的三嗪衍生物 |
| GB202108249D0 (en) * | 2021-06-09 | 2021-07-21 | Univ Of Sussex | Compounds |
| WO2023020604A1 (zh) * | 2021-08-20 | 2023-02-23 | 南京大美生物制药有限公司 | 一种五元含氮杂环并杂芳基类衍生物及其用途 |
| CN118922188A (zh) * | 2021-12-08 | 2024-11-08 | 奇尼塔公司 | 嘧啶及其使用方法 |
| WO2024015531A2 (en) * | 2022-07-13 | 2024-01-18 | University Of Kentucky Research Foundation | Triazine lipids, lipid synthesis, and methods for inhibiting canonical nf kb transcriptional activity |
| CN114933594A (zh) * | 2022-07-20 | 2022-08-23 | 北京科翔中升医药科技有限公司 | 一种氟代三嗪类化合物、药物组合物及用途 |
| CN116003448B (zh) * | 2022-11-07 | 2024-06-11 | 淮阴工学院 | 一种含吲哚啉多烯键识别Aβ纤维的BODIPY近红外荧光探针及其制备方法 |
| WO2024187321A1 (zh) * | 2023-03-10 | 2024-09-19 | 甫康（上海）健康科技有限责任公司 | 含有egfr抑制剂的药物组合物及其制备方法和应用 |
| WO2025137105A1 (en) * | 2023-12-22 | 2025-06-26 | Deciphera Pharmaceuticals, Llc | Dual raf and tubulin inhibitors and methods of use thereof |
| WO2025181366A1 (en) * | 2024-03-01 | 2025-09-04 | Torqur Ag | Topical formulations of dual pi3k/mtor inhibitors |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1670550B2 (de) * | 1967-02-17 | 1973-04-26 | Deutsche Gold und Silber Scheide anstalt vormals Roessler, 6000 Frank fürt | Substituierte 2-amino-4-hydrazino6-piperazino-s-triazine |
| DE2013357A1 (en) * | 1970-03-20 | 1971-10-07 | Farbenfabriken Bayer AG,5O9O Lever kusen | Iminocarboxylic acid derivs in prepn of s-triazines |
| DE2712686C2 (de) * | 1977-03-23 | 1986-09-04 | Bayer Ag, 5090 Leverkusen | 4-Triazinyl-4'-benzoxazolyl- bzw. 4'-phenyl-stilben-derivate |
| JPS59145250A (ja) * | 1983-02-04 | 1984-08-20 | Mitsubishi Chem Ind Ltd | アントラキノン化合物及びアントラキノン染料 |
| GB8612062D0 (en) * | 1986-05-17 | 1986-06-25 | Fbc Ltd | Herbicides |
| EP0629622B1 (en) * | 1992-02-28 | 1998-11-11 | Zenyaku Kogyo Kabushikikaisha | S-triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient |
| CA2197091A1 (en) * | 1994-08-08 | 1996-02-22 | Fusao Ueda | Triazine derivative and medicine |
| AU764479B2 (en) * | 1998-10-29 | 2003-08-21 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme |
| AU3078000A (en) * | 1999-01-25 | 2000-08-07 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compounds and antitumor agents containing the same as the active ingredient |
| US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| JP3836436B2 (ja) * | 2001-04-27 | 2006-10-25 | 全薬工業株式会社 | 複素環式化合物及びそれを有効成分とする抗腫瘍剤 |
| ATE468336T1 (de) * | 2002-03-15 | 2010-06-15 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
| BR0304925A (pt) * | 2002-05-30 | 2004-09-28 | Solvay Pharm Bv | Compostos, composições farmacêuticas, e, uso dos compostos |
| WO2004000820A2 (en) * | 2002-06-21 | 2003-12-31 | Cellular Genomics, Inc. | Certain aromatic monocycles as kinase modulators |
| CA2515132C (en) * | 2003-02-07 | 2012-01-03 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrroles useful as inhibitors of protein kinases |
| WO2005011703A1 (en) * | 2003-08-04 | 2005-02-10 | Akzo Nobel N.V. | 2-cyano-1,3,5-triazine-4,6-diamine derivatives |
| AR045944A1 (es) * | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
| TWI381841B (zh) * | 2005-03-11 | 2013-01-11 | Zenyaku Kogyo Kk | An immunosuppressive agent and an antitumor agent containing a heterocyclic compound as an active ingredient |
| EP2532667A1 (en) * | 2005-09-30 | 2012-12-12 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
| GB0520657D0 (en) * | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
| PL2041139T3 (pl) * | 2006-04-26 | 2012-05-31 | Hoffmann La Roche | Związki farmaceutyczne |
| BRPI0714908B8 (pt) * | 2006-08-08 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende |
| WO2008032033A1 (en) * | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008072850A1 (en) * | 2006-12-11 | 2008-06-19 | Amorepacific Corporation | Triazine derivatives having inhibitory activity against acetyl-coa carboxylase |
| ES2381895T3 (es) * | 2007-02-06 | 2012-06-01 | Novartis Ag | Inhibidores de PI 3-quinasa y métodos para su uso |
| WO2009093981A1 (en) | 2008-01-23 | 2009-07-30 | S Bio Pte Ltd | Triazine compounds as kinase inhibitors |
| EP2082777A1 (en) * | 2008-01-27 | 2009-07-29 | Oncotherm Kft. | Flexible and porous large-area electrode for heating |
| DE202008001253U1 (de) * | 2008-01-28 | 2008-04-10 | Mirror Image Ag | Bildanzeigegerät |
| EA020317B1 (ru) * | 2008-05-23 | 2014-10-30 | УАЙТ ЭлЭлСи | ТРИАЗИНЫ КАК ИНГИБИТОРЫ КИНАЗЫ PI3 И mTOR |
| GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
-
2008
- 2008-11-10 GB GB0821219A patent/GB2465405A/en not_active Withdrawn
-
2009
- 2009-11-10 NZ NZ592617A patent/NZ592617A/en active IP Right Revival
- 2009-11-10 MX MX2011004889A patent/MX2011004889A/es active IP Right Grant
- 2009-11-10 BR BRPI0921709-6A patent/BRPI0921709B1/pt active IP Right Grant
- 2009-11-10 JP JP2011535182A patent/JP5738768B2/ja active Active
- 2009-11-10 SI SI200931578A patent/SI2364302T1/sl unknown
- 2009-11-10 US US13/128,436 patent/US8921361B2/en active Active
- 2009-11-10 AU AU2009312464A patent/AU2009312464B2/en active Active
- 2009-11-10 EP EP09764032.0A patent/EP2364302B1/en active Active
- 2009-11-10 CN CN200980144674.6A patent/CN102209714B/zh active Active
- 2009-11-10 LT LTEP09764032.0T patent/LT2364302T/lt unknown
- 2009-11-10 RU RU2011114559/04A patent/RU2537945C2/ru active
- 2009-11-10 CA CA2741990A patent/CA2741990C/en active Active
- 2009-11-10 DK DK09764032.0T patent/DK2364302T3/en active
- 2009-11-10 HR HRP20161769TT patent/HRP20161769T1/hr unknown
- 2009-11-10 ES ES09764032.0T patent/ES2609296T3/es active Active
- 2009-11-10 KR KR1020117013081A patent/KR101749192B1/ko active Active
- 2009-11-10 WO PCT/IB2009/007404 patent/WO2010052569A2/en not_active Ceased
-
2011
- 2011-05-05 IL IL212726A patent/IL212726A/en active IP Right Grant
- 2011-06-09 ZA ZA2011/04298A patent/ZA201104298B/en unknown
-
2015
- 2015-02-04 JP JP2015020319A patent/JP6047184B2/ja active Active
-
2017
- 2017-01-04 SM SM201700006T patent/SMT201700006B/it unknown
- 2017-01-05 CY CY20171100019T patent/CY1118438T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012508223A5 (enExample) | ||
| JP5461189B2 (ja) | キナーゼ活性の阻害剤 | |
| JP6528957B2 (ja) | Ｔｒｋ阻害化合物 | |
| TWI446910B (zh) | 調節ｈｓｐ９０活性的三唑化合物 | |
| US20250122188A1 (en) | Modulators of the integrated stress pathway | |
| CN101072759B (zh) | 调节hsp90活性的三唑化合物 | |
| TWI469970B (zh) | 調節ｈｓｐ９０活性之咪唑化合物 | |
| RU2011114559A (ru) | Триазин, пиримидин, аналоги пиридина и их применение в качестве терапевтических агентов и диагностических проб | |
| JP2010514688A (ja) | インドール−４−イルピリミジニル−２−イル−アミン誘導体およびサイクリン依存性キナーゼ阻害剤としてのその使用 | |
| TW201912639A (zh) | Ｓｈｐ２之八氫環戊烷并[c]吡咯別構抑制劑 | |
| JP2014511869A5 (enExample) | ||
| RU2007100136A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| JP2008526887A (ja) | カンナビノイド受容体に作用する新規なヘテロピロール類似体 | |
| JP2014525444A5 (enExample) | ||
| KR20090091306A (ko) | 암, 염증 및 바이러스 감염 치료용 ｃｄｋ 억제제로서의 헤테로아릴-헤테로아릴 화합물 | |
| RU2012134306A (ru) | Азотосодержащие производные гетероарилов | |
| JP2010513272A5 (enExample) | ||
| RU2019132212A (ru) | Селективные ингибиторы hdac6 | |
| JPWO2021170109A5 (enExample) | ||
| BR112019024109A2 (pt) | Composto, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de modulação de uma resposta imune em um indivíduo com um tumor, e, método de profilaxia ou tratamento | |
| AU2004229392A1 (en) | Tie-2 modulators and methods of use | |
| JP2019511466A (ja) | オレキシン受容体調節因子としてのハロ置換ピペリジン | |
| JP2015524483A5 (enExample) | ||
| WO2015012400A1 (ja) | グリシントランスポーター阻害物質 | |
| WO2009128661A2 (ko) | 신규 벤조옥사진 벤즈이미다졸 유도체, 이를 포함하는 약학 조성물 및 이의 용도 |